Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study involves patients with Acute Myeloid Leukemia, a type of blood cancer that affects the bone marrow and blood. The study focuses on patients whose leukemia has specific genetic changes, either a change in a gene called NPM1 or rearrangements involving a gene called KMT2A. The treatment being tested is JNJ-75276617, also known as bleximenib, which is given in the form of film-coated tablets taken by mouth. Some patients will receive bleximenib while others will receive placebo.

The purpose of this study is to find out if adding bleximenib to the standard intensive chemotherapy treatment can help patients live longer without their disease getting worse compared to receiving standard chemotherapy with placebo. The standard treatment includes chemotherapy to put the disease into remission, followed by additional chemotherapy to strengthen this response, and then maintenance therapy to help keep the disease under control.

During the study, patients will receive either bleximenib or placebo together with their regular intensive chemotherapy treatment. The study follows patients through the initial treatment phase aimed at achieving remission, a consolidation phase to reinforce the response, and then a maintenance phase. Neither the patients nor their doctors will know whether they are receiving bleximenib or placebo during the study. The study will monitor how well the treatment works and track patient outcomes over time.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and treatment assignment

    At the beginning of the study, you will be randomly assigned to receive either bleximenib or placebo. A placebo is an inactive substance that looks like the actual medication but contains no active ingredient.

    Neither you nor your doctor will know which treatment you are receiving. This is called a double-blind study design.

    The study medication will be given as film-coated tablets taken by mouth.

  2. Step 2

    Remission induction chemotherapy phase

    You will receive intensive chemotherapy aimed at achieving complete remission. Complete remission means that the leukemia cells are no longer detectable in your blood and bone marrow.

    During this phase, you will also receive either bleximenib tablets or placebo tablets in combination with the chemotherapy.

    The study medication (bleximenib or placebo) will be available in two strengths: 50 mg and 100 mg tablets.

  3. Step 3

    Consolidation chemotherapy phase

    After achieving complete remission, you will receive consolidation chemotherapy. This treatment is designed to eliminate any remaining leukemia cells and reduce the risk of the disease returning.

    You will continue taking either bleximenib tablets or placebo tablets along with the consolidation chemotherapy.

  4. Step 4

    Maintenance therapy phase

    Following the completion of consolidation chemotherapy, you will enter the maintenance therapy phase.

    During this phase, you will continue taking either bleximenib tablets or placebo tablets by mouth.

    The purpose of maintenance therapy is to help prevent the leukemia from returning.

  5. Step 5

    Monitoring and assessments

    Throughout all phases of the study, your health will be closely monitored through regular medical examinations, blood tests, and bone marrow assessments.

    Your kidney and liver function will be checked to ensure they are working adequately.

    Your white blood cell count will be monitored. White blood cells are cells in your blood that help fight infections.

    Your doctor will assess your overall physical condition using the WHO/ECOG performance status, which is a scale that measures how the disease affects your daily living abilities.

Who can join the trial?

7 criteria

  • You must be 18 years of age or older at the time you agree to join the study
  • You must have a new diagnosis of Acute Myeloid Leukemia, which is a type of blood cancer where abnormal white blood cells grow rapidly in the bone marrow. Your disease must show at least 10% blasts (immature blood cells) in your bone marrow (the soft tissue inside bones where blood cells are made) or blood
  • Your leukemia must have specific genetic changes: either a mutation in the NPM1 gene (a change in a specific gene) or rearrangements involving the KMT2A gene (changes in the structure of another specific gene)
  • Your doctor must determine that you are healthy enough to receive intensive chemotherapy, which is strong cancer treatment given through the vein
  • Your performance status must be 2 or less on the WHO/ECOG scale, which means you are able to care for yourself and are up and about for at least half of your waking hours
  • Your kidneys and liver must be working well enough before you are assigned to a treatment group
  • Your white blood cell count (the number of infection-fighting cells in your blood) must be less than 25 times 10 to the power of 9 per liter

Who cannot join the trial?

5 criteria

  • The source data does not provide specific exclusion criteria for this clinical trial
  • Exclusion criteria are reasons why a person cannot take part in a study, but these details were not included in the available information
  • This trial is studying a treatment called bleximenib for adults with a specific type of blood cancer called Acute Myeloid Leukemia, which is a cancer that affects blood cells and bone marrow
  • The study focuses on patients who have certain genetic changes in their cancer cells, specifically NPM1 mutation or KMT2A rearrangement, which are specific abnormalities in the cancer cells
  • Participants must be suitable for intensive chemotherapy, which means strong cancer-fighting medications given in high doses
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Bleximenib

    is an investigational medication being studied in this trial. It is given in combination with standard chemotherapy during the initial treatment phase to help fight leukemia, and then continued as maintenance therapy. The purpose is to see if adding this medication to standard treatment can help prevent the cancer from coming back or getting worse in patients with certain types of acute myeloid leukemia.

  • Standard induction chemotherapy

    refers to the initial intensive treatment used to put the leukemia into remission. This means using powerful medications to kill as many cancer cells as possible and help the patient achieve a state where the disease is no longer detectable.

  • Consolidation chemotherapy

    is additional treatment given after the initial therapy to eliminate any remaining cancer cells and reduce the chance of the leukemia returning. This helps to strengthen and maintain the remission achieved with the induction treatment.

What is already known about the treatment

Bleximenib – Bleximenib is an investigational medication currently being studied in clinical trials for the treatment of acute myeloid leukemia, specifically in patients with certain genetic mutations (NPM1-mutant or KMT2A-rearranged). This drug is administered in combination with standard chemotherapy during the induction and consolidation phases, followed by maintenance therapy, and is being compared against placebo in a controlled study. The medication works at the molecular level by targeting specific pathways involved in leukemia cell growth and survival, though it has not yet received approval for routine clinical use. Bleximenib belongs to the class of targeted cancer therapies designed to interfere with cancer cell processes while potentially reducing harm to normal cells.

Investigated diseases

Acute Myeloid Leukemia – Acute Myeloid Leukemia is a type of cancer that affects the blood and bone marrow. It occurs when the bone marrow begins to produce abnormal white blood cells called myeloblasts, which do not function properly. These abnormal cells multiply rapidly and crowd out healthy blood cells in the bone marrow. As the disease progresses, the number of normal red blood cells, white blood cells, and platelets decreases. This leads to symptoms such as fatigue, frequent infections, easy bruising, and bleeding. The condition develops quickly and requires prompt medical attention.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-522767-15-00Protocol codeHOVON 181 AMLEstimated enrolment1 027 patientsSponsorHaemato Oncology Foundation For Adults Netherlands

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).